Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

SBRT treatment safe and effective for stage I NSCLC, study finds

Stereotactic body radiotherapy is considered the treatment of choice for early-stage non-small-cell lung cancer if patients are inoperable because of additional medical conditions.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

New research from Rutgers Cancer Institute of New Jersey, Princeton University and other collaborators suggests that inactivation of an essential gene responsible for the cell survival process known as autophagy can suppress the growth of non-small-cell lung cancer tumors and render them more benign.

1 Jul 2013

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors.

26 Jun 2013

Pretreatment PET staging of LS-SCLC associated with improved survival

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Research findings may pave way for new strategy to combat lung cancer

Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.

19 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

Davis High School sophomore recipient of Blue and White Foundation grant

What started as a dinner-table conversation between a teen and his father has become a bonafide cancer research study for Matthew Lara, a Davis High School sophomore and the son of UC Davis Comprehensive Cancer Center medical oncologist and researcher Primo (Lucky) Lara Jr.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

New study reveals racial differences in initial treatment of NSCLC

The surgical management of non-small cell lung cancer in U.S. hospitals varies widely depending on the race of the patient, according to a new study.

22 May 2013

Small Cell Lung Cancer News and Research

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

SBRT treatment safe and effective for stage I NSCLC, study finds

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

Pretreatment PET staging of LS-SCLC associated with improved survival

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Research findings may pave way for new strategy to combat lung cancer

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Cancer immunotherapy shows promise in treating patients with metastatic tumors

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

New therapy for lung cancer produces manageable side effects

Davis High School sophomore recipient of Blue and White Foundation grant

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

New study reveals racial differences in initial treatment of NSCLC

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News